Pembrolizumab for Brain Tumor
This trial will test if the study drug pembrolizumab can help control cancer growth or shrink the cancer, and if it does cause side effects.
- Brain Tumor
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2021 Phase 3 trial • 453 Patients • NCT03066778
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
In which geographic regions is this research taking place?
"Various medical centres are recruiting patients for this clinical trial, including the University of Miami in Florida and Md Anderson Cancer Center in Texas. Moreover, there are 11 other locations where participants can be recruited from."
Could you enumerate any other experiments utilizing Pembrolizumab?
"Currently, the total number of active trials researching Pembrolizumab is 962 with 122 being in Phase 3. Houston, Texas serves as the primary site for these clinical studies; however, a grand total of 35769 locations are running experiments involving this medication."
What is the participant cap for this clinical trial?
"At this time, applicants are not being accepted for the specified clinical trial. It was first released on January 22nd 2016 and last modified on March 4th 2022. Luckily, there are 1316 trials seeking individuals with glioma and 962 studies searching for Pembrolizumab participants at present."
Are recruitment opportunities still available for participants in this trial?
"Data from clinicaltrials.gov confirms that enrollment for this trial has been completed, as the study was first published on January 22nd 2016 and last updated on March 4th 2022. Nonetheless, there are 2278 other medical studies actively seeking participants at present."